Literature DB >> 18085396

MPO-ANCA-positive IgA nephropathy successfully treated with tonsillectomy.

Noriko Ogawa1, Shozo Yano2, Yuko Yamane2, Masateru Nishiki2, Toru Yamaguchi2, Tatsuo Tsukamoto3, Eri Muso3, Toshitsugu Sugimoto2.   

Abstract

A 20-year-old Japanese woman was admitted to a hospital because of gross hematuria. She was diagnosed with IgA nephropathy with a poor prognosis, based on the formation of many crescents in the glomerulus and monocyte infiltration in the interstitium in a renal biopsy specimen in February 2003. Myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA) was not identified at that time. After treatment with high-dose steroid pulse therapy and heparin/warfarin, her urinary protein improved, to 0.5 g/day. However, 1 year after the steroid pulse therapy, urinary protein was increased to 1.2 g/day, associated with repeated episodes of tonsillitis. A second renal biopsy was performed, and showed an improving tendency, compared to the findings of the previous one, although some crescent formation and adhesions of Bowman's capsule remained. Interestingly, MPO-ANCA was positive in the serological examination done at this time. One month and a half after the second renal biopsy, she had a tonsillectomy, followed by a regimen of 5 mg oral prednisolone daily, in order to prevent the progression of IgA nephropathy. After the tonsillectomy, her urinary protein level was markedly improved, at 0.14 g/day. Her creatinine clearance was ameliorated, at 102 ml/min, and in addition, MPO-ANCA had disappeared. This case suggests that an inflammation such as tonsillitis may be associated not only with the activity of IgA nephropathy but also with the production of MPO-ANCA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18085396     DOI: 10.1007/s10157-007-0506-3

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  24 in total

1.  Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy.

Authors:  O Hotta; M Miyazaki; T Furuta; S Tomioka; S Chiba; I Horigome; K Abe; Y Taguma
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

Review 2.  The IgA nephropathy treatment dilemma.

Authors:  G B Appel; M Waldman
Journal:  Kidney Int       Date:  2006-06       Impact factor: 10.612

Review 3.  Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences.

Authors:  E C Hagen; B E Ballieux; L A van Es; M R Daha; F J van der Woude
Journal:  Blood       Date:  1993-04-15       Impact factor: 22.113

4.  IgA glomerulonephritis associated with microscopic polyangiitis or Churg-Strauss syndrome.

Authors:  C Richer; L Mouthon; P Cohen; P Buchet; I Royer; C Guettier; L Guillevin
Journal:  Clin Nephrol       Date:  1999-07       Impact factor: 0.975

5.  Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis.

Authors:  A C Allen; E M Bailey; J Barratt; K S Buck; J Feehally
Journal:  J Am Soc Nephrol       Date:  1999-08       Impact factor: 10.121

6.  Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy.

Authors:  H Yokoyama; T Wada; K Furuichi; C Segawa; M Shimizu; K Kobayashi; S Su; N Mukaida; K Matsushima
Journal:  J Leukoc Biol       Date:  1998-04       Impact factor: 4.962

7.  ANCA-positive glomerulonephritis and IgA nephropathy in a patient on propylthiouracil.

Authors:  Michael J Winters; R Morrison Hurley; David S Lirenman
Journal:  Pediatr Nephrol       Date:  2002-04       Impact factor: 3.714

8.  ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits.

Authors:  M Haas; J Jafri; S M Bartosh; S L Karp; S G Adler; S M Meehan
Journal:  Am J Kidney Dis       Date:  2000-10       Impact factor: 8.860

Review 9.  Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation.

Authors:  S J Martin; M A Audrain; T Baranger; A Moreau; J Dantal; A Testa; V L Esnault
Journal:  Am J Kidney Dis       Date:  1997-01       Impact factor: 8.860

10.  Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy.

Authors:  I C Moura; M N Centelles; M Arcos-Fajardo; D M Malheiros; J F Collawn; M D Cooper; R C Monteiro
Journal:  J Exp Med       Date:  2001-08-20       Impact factor: 14.307

View more
  4 in total

1.  Combined membranous nephropathy and crescentic glomerulonephritis with concurrent anti-glomerular basement membrane antibody and myeloperoxidase-specific anti-neutrophil cytoplasmic antibody.

Authors:  Yoichi Iwafuchi; Takashi Morita; Yuko Oyama; Akira Kamimura; Shigeru Miyazaki; Ichiei Narita
Journal:  CEN Case Rep       Date:  2013-01-30

2.  ANCA-positive IgA nephropathy without necrotising or crescentic glomerulonephritis: a clinical conundrum.

Authors:  Abhilash Koratala; Xu Zeng; Amir Kazory
Journal:  BMJ Case Rep       Date:  2017-11-23

3.  Clinical significance of ANCA positivity in patients with IgA vasculitis: a retrospective monocentric study.

Authors:  Jae Yeon Kim; Hyeok Choi; Minyoung Kevin Kim; Soo Bin Lee; Yong-Beom Park; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2019-08-01       Impact factor: 2.631

4.  Clinical features of IgA nephropathy with serum ANCA positivity: a retrospective case-control study.

Authors:  Ya-Zi Yang; Su-Fang Shi; Yu-Qing Chen; Min Chen; Yi-He Yang; Xin-Fang Xie; Rong Zou; Ji-Cheng Lv; Li-Jun Liu; Hong Zhang
Journal:  Clin Kidney J       Date:  2015-08-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.